EYPT
EyePoint Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | +2 | 47.58M | $680.27M | +5 | −4 |
| Q1 2026 | 79 | +9 | 48.20M | $619.80M | +12 | −3 |
| Q4 2025 | 69 | +1 | 44.57M | $814.29M | +2 | −1 |
| Q3 2025 | 14 | -1 | 22.98M | $327.28M | n/a | −1 |
| Q2 2025 | 12 | 0 | 22.66M | $213.25M | n/a | n/a |
| Q1 2025 | 9 | -1 | 13.73M | $74.43M | n/a | −1 |
| Q4 2024 | 10 | 0 | 15.37M | $114.47M | +1 | −1 |
| Q3 2024 | 9 | -2 | 10.25M | $81.94M | n/a | −2 |
| Q2 2024 | 11 | n/a | 10.63M | $92.49M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 3.59M | n/a | $31.25M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 2.50M | n/a | $21.77M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Citadel Advisors ✦ | 1.35M | n/a | $11.78M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Geode Capital Management ✦ (passive) | 1.03M | n/a | $8.98M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Point72 Asset Management ✦ | 630.77K | n/a | $5.49M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 600.40K | n/a | $5.22M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 580.72K | n/a | $5.05M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 152.80K | n/a | $1.33M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 107.76K | n/a | $937,478 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | D. E. Shaw & Co. ✦ | 48.96K | n/a | $425,943 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 28.72K | n/a | $249,890 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 40.00K shares, $515 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 10.60K sh @ 4.93 · $52,258
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology